Sanofi-Synthelabo, Inc.

Throughout June close to 50 communities will be gathering across Canada to raise funds for type 1 diabetes researchTORONTO, May 31, 2024 (GLOBE NEWSWIRE) -- The JDRF Walk to Cure Diabetes is the largest fundraising event in Canada that brings together the type 1 diabetes (T1D) community to raise funds for T1D research. A fun-filled family and community celebration, the Walk has raised more than $140 million to date making it one of the longest running and most successful fundraising events in the country. Throughout June, close to 50 Walk events will be held across the country. The collective fundraising goal is $3.7 million that will help support JDRF’s mission to cure T1D. 2024 marks the 50th anniversary of JDRF Canada, and this event pays tribute to the organization’s grassroots foundations. JDRF is excited to bring together our T1D community to recognize 50 years of progress, momentum and breakthroughs in T1D research. T1D is an autoimmune disease that affects close to 300,000 Canadians. For over 100 years, the only available treatment has been insulin, and even with careful management there is the risk of diabetes-related complications like kidney failure, blindness, amputation and even death. Canada has one of the fastest-growing rates of diagnosis in the world, and we don’t know why. There is currently no medication or therapy that can improve disease outcomes and no cure. Continued investment in ground-breaking research, such as stem cell-based treatments that can produce insulin in those living with the disease, is crucial for improved treatments and cures. Quotes: “The Walk is truly a special event and feels even more meaningful as we mark 50 years of JDRF in Canada,” says Jessica Diniz, President and CEO of JDRF Canada. “This organization began with dedicated parents looking drive T1D research, and we honour that legacy every year at the Walk, bringing together the T1D community for this singular goal. Funds raised from the JDRF Walk to Cure Diabetes will help improve lives of Canadians living with T1D by accelerating life-changing breakthroughs to treat, prevent and cure T1D.” The Walk’s newest sponsor, Sanofi, has come onboard as National Awareness Partner. "Building on our strong legacy in diabetes care, Sanofi Canada's commitment to helping Canadians living with diabetes goes beyond medicine,” says Ahmed Moussa, General Manager of General Medicines at Sanofi Canada. “We're proud to sponsor the JDRF Walk to Cure Diabetes to provide an opportunity for people across Canada to come together and raise awareness about type 1 diabetes, ensuring that education and support are available to all." Abbott’s Diabetes Care division has returned as the Walk’s National Premier Partner. “At Abbott, we deeply value our long-standing commitment to supporting JDRF, the community and people living with diabetes,” says Luz Herrera, General Manager, Abbott’s Diabetes Care division in Canada. “As part of this commitment, Abbott is honoured to continue our partnership with JDRF in supporting families and accelerating research and innovation in treating type 1 diabetes.” Learn more about the 2024 JDRF Walk to Cure Diabetes and help us move T1D research forward faster: jdrfwalk.ca About JDRF JDRF is the leading global organization funding type 1 diabetes (T1D) research. Our mission is to accelerate life-changing breakthroughs to cure, prevent and treat T1D and its complications We are an organization built on a grassroots model of people connecting in their local communities, collaborating regionally for efficiency and broader fundraising impact, and uniting on a national stage to pool resources, passion, and energy. We collaborate with academic institutions, governments, and corporate and industry partners to develop and deliver a pipeline of innovative therapies to people living with T1D. Our staff and volunteers throughout Canada and five international affiliates are dedicated to advocacy, community engagement and our vision of a world without T1D. For more information, please visit jdrf.ca. About Abbott Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 115,000 colleagues serve people in more than 160 countries. Connect with us at www.abbott.com, on LinkedIn at www.linkedin.com/company/abbott-on Facebook at www.facebook.com/Abbott and on Twitter @AbbottNews. About Sanofi Sanofi is an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions. In Canada, Sanofi employs over 2,000 people and invests annually of 20% of its revenue in biopharma research, representing CAD $1.2 billion in R&D over the last decade, creating jobs, business, and opportunities throughout the country. From our state-of-the-art Campus in Toronto, we research, develop, manufacture, commercialize and distribute Sanofi products to people in this country and around the world. In 2024, we are celebrating 110 years of heritage. What started as a small laboratory in May of 1914, has evolved to become the largest biomanufacturing facility in Canada. Today, we remain committed to discovering, developing, and delivering innovative medicine and vaccine solutions for people that need them. For more information: Ruth KapelusNational Content & Media Relations Manager, JDRF CanadaT. 647.789.2322E. rkapelus@jdrf.ca

Four $50,000 financial grants will be awarded to deserving Canadian public high schools to enhance scientific learning. Recipients can use the funds to renovate existing laboratory facilities, purchase new scientific equipment, develop programs to enhance the impact of labs or any combination of the above. TORONTO, March 19, 2024 /CNW/ - sanofi-aventis Canada inc. (Sanofi Canada) is pleased to announce that applications for the 2024 Sanofi Biogenius Canada Grants are now open. Part of Sanofi Canada's longstanding commitment to improving access to hands-on science, technology, engineering, and mathematics (STEM) learning, the $50,000 financial grants aim to provide necessary resources to Canadian public high schools to advance STEM education and inspire students to embrace scientific discovery. Stephanie Veyrun-Manetti Canada Country Lead and General Manager, Specialty Care, Sanofi Canada "At Sanofi Canada, we strongly believe in nurturing the upcoming generation of talent and take pride in providing support to Canadian public high schools to advance STEM education. The Sanofi Biogenius Canada Grants help to create equal opportunities for all students to excel in STEM fields, enabling them to build the skills required for future success. Since launching the program in 2021, Sanofi has witnessed the tremendous impact it has had on propelling students' scientific learning. We encourage teachers, school administrators, and principals across Canada to apply and join us in our efforts to foster a culture of innovation and scientific exploration." Reni Barlow Executive Director, Youth Science Canada "Canadian educators demonstrate extraordinary commitment and creativity, delivering high-quality science education despite limited and often outdated resources. The Sanofi Biogenius Canada Grants transform selected schools, strengthening STEM programs, benefiting teachers and students, and shaping the future of STEM education." Nathan Kostiuk Western Regional Coordinator, Let's Talk Science "As innovation becomes more central to our world, the need for individuals who can pursue careers in STEM will only grow. STEM education and hands-on learning are essential for students' future success, however, a majority of Canadian students lose interest in STEM courses before completing high school. Let's Talk Science and Sanofi Canada share a common goal of empowering students to embrace science, technology, and innovation, and we believe that providing schools with the necessary resources is essential to advance science education. The Sanofi Biogenius Canada Grants will continue to have a long-lasting impact on each school that receives these funds." Public high schools across Canada can apply for the Sanofi Biogenius Canada Grants from March 15 to May 15, 2024. Applicants must demonstrate a commitment to hands-on STEM learning opportunities for all students, no matter their sexual orientation, gender identity and/or expression, family status or location. Recipients can use the funds to renovate existing laboratory facilities, purchase new scientific equipment, develop programs to enhance the impact of labs or any combination of the above. Four Canadian public high schools will be selected to receive a Sanofi Biogenius Canada Grant. To apply for a Sanofi Biogenius Canada Grant or for more information, visit . Concurrently, the Sanofi Biogenius Canada Competition is also underway, celebrating the best research projects from across the country, encouraging students to follow their curiosity and pursue ground-breaking STEM projects. Through both the regional and national Sanofi Biogenius Canada Competitions, students gain access to a network of life-minded individuals and mentors that extend far beyond the classroom and open doors to future success. To learn more about the Sanofi Biogenius Canada Competition, visit . About The Sanofi Biogenius Canada Grants The Sanofi Biogenius Canada Grants help provide better access to hands-on STEM learning by supporting Canadian public high schools with financial grants to update lab equipment, launch new science programs and take science education to the next level. About The Sanofi Biogenius Canada Competition The Sanofi Biogenius Canada Competition encourages students from coast-to-coast and any background to break barriers and explore real-life research projects with a focus on health sciences, life sciences and biotechnology. The competition is hosted in partnership with Youth Science Canada, as part of its regional and Canada-wide Science Fair (CWSF). About Sanofi Sanofi is an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people's lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions. In Canada, we employ over 2,000 people and invest annually 20% of our revenue in biopharma research, representing CAD $1.2 billion in R&D over the last decade, creating jobs, business, and opportunity throughout the country. We're also on track to deliver over $2 billion in new infrastructure investments by 2028, including two new vaccine manufacturing facilities at our Toronto Campus. In 2024, we are celebrating 110 years of heritage dedicated to developing innovative health solutions for Canadians. What started as a small laboratory in May of 1914, recognized for having advanced some of the greatest contributions to public health, both nationally and globally, has evolved to become the largest biomanufacturing facility in Canada. SOURCE Sanofi-Aventis Canada Inc.

TORONTO, Feb. 20, 2024 /CNW/ - JDRF and Sanofi Canada are announcing a partnership aimed at amplifying awareness around type 1 diabetes (T1D), a chronic autoimmune condition, and the role screening could play in the early detection of this disease. Nationally, the number of individuals diagnosed with T1D is growing at an estimated 4.4% per year. This places Canada among the countries in the world with the highest rate of new T1D cases each year. While many believe T1D is only diagnosed in childhood and adolescence, diagnosis in adulthood is common and accounts for over 50% of all T1D cases. Traditionally, a diagnosis of T1D follows the onset of clinical symptoms, such as excessive thirst, frequent urination, and weight loss, however, the underlying autoimmune damage on pancreatic beta cells begins long before these signs become apparent. The evolution of T1D unfolds through three discernible stages, with the initial 'silent' phase characterized by the presence of autoantibodies and no overt symptoms. Creating awareness of the stages leading to the onset of clinical disease could mitigate the risk of diabetic ketoacidosis (DKA), a life-threatening condition that often accompanies the diagnosis of T1D. Early detection could help keep people out of the hospital and reduce the significant financial burden on the healthcare system. Jessica Diniz, President and CEO, JDRF Canada Through this partnership, JDRF Canada and Sanofi Canada will work to increase awareness of T1D and the potential of screening to benefit individuals and families at risk of the disease in the future. T1D screening is a key pillar of JDRF's strategy internationally, as it has the power to detect who is at risk and, in turn, will enable the delivery of education and support to improve outcomes. This new partnership will focus on disseminating resources and support for Canadians at risk of developing T1D and their healthcare providers, to foster a culture of active health management. Ahmed Moussa, General Manager, General Medicines, Sanofi Canada At Sanofi, we believe diabetes education is a critical tool for individuals living with the condition and for the healthcare professionals who care for them. At the core of our partnership with JDRF lies a shared commitment to shed light on the journey towards the onset of T1D. By illuminating the stages preceding clinical symptoms, we aim to equip individuals with the knowledge needed to make informed decisions about their health. Early detection can empower individuals to face an eventual diagnosis with the education and support to preemptively manage their condition. About JDRF JDRF is the leading global organization funding type 1 diabetes (T1D) research. Our mission is to accelerate life-changing breakthroughs to cure, prevent and treat T1D and its complications. We are an organization built on a grassroots model of people connecting in their local communities, collaborating regionally for efficiency and broader fundraising impact, and uniting on a national stage to pool resources, passion, and energy. JDRF partners across the full T1D development pipeline – including academic institutions, governments and corporations – to fund research and advocate for the delivery of innovative therapies to people living with T1D. Our staff and volunteers throughout Canada and five international affiliates are dedicated to advocacy, community engagement and our vision of a world without T1D. For more information, please visit jdrf.ca. About Sanofi Sanofi is an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people's lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions. In Canada, Sanofi employs over 2,000 people and invests annually of 20% of its revenue in biopharma research, representing CAD $1.2 billion in R&D over the last decade, creating jobs, business, and opportunities throughout the country. From our state-of-the-art Campus in Toronto, we research, develop, manufacture, commercialize and distribute Sanofi products to people in this country and around the world. In 2024, we are celebrating 110 years of heritage. What started as a small laboratory in May of 1914, has evolved to become the largest biomanufacturing facility in Canada. Today, we remain committed to discovering, developing, and delivering innovative medicine and vaccine solutions for people that need them. SOURCE Sanofi-Aventis Canada Inc.